FarmaKology Newsletter - Issue #67

Feb 09, 2021

Today's Startup

NAVAN Technologies, Inc.

NAVAN Technologies, Inc. is an enabling technology company commercializing a novel non-viral delivery platform to radically accelerate genetic engineering of human primary cells. The patented NanoStraw technology provides direct intracellular access into hard-to-transfect primary human cells for efficacious delivery of any cargo. By using a physical, non-perturbative mechanism for delivery, the challenges of viral-based cell manufacturing (time, cost and technical difficulties) are eliminated, resulting in fewer, faster operational steps.

News

Turn Therapeutics Announces First Subjects Enrolled in Human Clinical Trial for the Treatment and Prevention of COVID-19

Turn Therapeutics, a biotechnology company specializing in advanced wound care and infection control, today announced enrollment of the first subjects in its COVID-19 treatment and prevention clinical trial. Turn’s flagship product, Hexagen, will be administered intranasally and studied as a method for reducing viral load, as well as uptake, at the critical infection points that line the nasal passage. The company expects enrollment to be swift, with multiple patients and healthcare providers enrolled just today. An initial data readout is expected in early March 2021.

Bristol Myers Squibb Receives European Commission Approval for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis

Bristol Myers Squibb announced that the European Commission has granted full Marketing Authorization for Inrebic® (fedratinib) for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, who are Janus Associated Kinase inhibitor naïve or have been treated with ruxolitinib.

Evotec and Related Sciences enter integrated drug discovery and development partnership

Evotec SE announced today that the Company has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period.

OliX Pharmaceuticals Launches New Subsidiary to Develop mRNA Vaccines and Therapeutics

OliX Pharmaceuticals, a leading developer of RNAi therapeutics, has announced the establishment of mCureX Therapeutics, Inc., a subsidiary focused on the research and development of messenger RNA (mRNA) vaccines and therapeutics.